ASH 2019 | BPDCN common in the setting of prior/concomitant hemoncs

Naveen Pemmaraju

Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX, discusses the characteristics and outcomes of blastic plasmacytoid dendritic cell neoplasm (BPDCN) patients in the modern era from almost a decade of follow-up. He highlights how BPDCN commonly presents in the setting of prior or concomitant hematologic malignancies, and that treatment on clinical trials has now become the most commonly employed therapeutic strategy for BPDCN. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter